genocea biosciences

Quick Analysis: Canadian Solar Inc. (NASDAQ:CSIQ), Genocea Biosciences Inc …
www.citizendispatch.com

It has two product candidates in Phase II clinical development: GEN-003 and GEN-004. It also has product candidates, which are GEN-001, GEN-002 and GEN-005 in pre-clinical development for diseases, including genital herpes, chlamydia and malaria.

6
Like
Save
Genocea Biosciences files for $50 million stock offering
www.bostonglobe.com

Biopharmaceutical company Genocea Biosciences, Inc., said Thursday it planned to raise $50 million by selling 3.85 million additional shares of stock at $13 a share. The Cambridge-based company, that develops vaccines and immunotherapies, expects to …

4
Like
Save
Why Genocea Biosciences Inc Stock Dropped Today
www.fool.com

The company plans to use the proceeds of the offering to support the clinical development of GEN-003 and GEN-004, which are both currently in phase 2 development as treatment options for genital herpes and pneumococcus, respectively. The market didn't …

10
Like
Save
Morning Buzz: Genocea Biosciences, Inc. (NASDAQ:GNCA), Conatus …
www.stocktranscript.com

On 20 May, Genocea Biosciences, Inc. (NASDAQ:GNCA) announced positive top-line data from a Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. During the 28-day observation period immediately after completion of …

8
Like
Save
Today's Hot List: Genocea Biosciences, Inc. (NASDAQ:GNCA), Immunomedics …
www.stocktranscript.com

On 20 May, Genocea Biosciences, Inc. (NASDAQ:GNCA), announced positive top-line data from a Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. During the 28-day observation period immediately after completion of …

2
Like
Save
Don't Miss: Genocea Biosciences, Inc. (NASDAQ:GNCA), Annaly Capital …
www.stocktranscript.com

On 21 May, Genocea Biosciences, Inc. (NASDAQ:GNCA) announced positive top-line data from a Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. During the 28-day observation period immediately after completion of …

7
Like
Save
Pre-Open Stock Movers 05/20: (SRPT) (ISR) (PBY) Higher; (LPTN) (ETSY …
www.streetinsider.com

Genocea Biosciences (NASDAQ: GNCA) 21.5% HIGHER; announced positive top-line data from a Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. During the 28-day observation period immediately after completion of …

7
Like
Save
What You May Have Missed in Biotech: Eye Drug Fails, Ear Drug Flops, and …
www.forbes.com

based Genocea Biosciences reported success this week with a mid-stage clinical trial of its experimental treatment for genital herpes. The study of 310 patients with genital herpes showed that the Genocea drug was able to significantly reduce viral …

4
Like
Save
Genocea Biosciences (GNCA) Jumps: Stock Gains 8.8%
www.zacks.com

The upside was owing to the company's announcement of positive top-line data from a Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. This led to far more shares changing hands than in a normal session. The move …

9
Like
Save
ETF Preview: ETFs Lower, Stocks Mostly Flat Ahead of FOMC Meeting Minutes
www.nasdaq.com

Biotechnology fund iShares NASDAQ Biotechnology Index (IBB) was flat. Genocea Biosciences (GNCA) was up 27% after announcing positive top line data from a phase 2 trial of its GEN-003 for the treatment of genital herpes. The was a 'highly statistically …

10
Like
Save